Literature DB >> 781466

Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease.

E J Feinglass, F C Arnett, C A Dorsch, T M Zizic, M B Stevens.   

Abstract

1. Among patients with SLE, 71 (51%) had significant neuropsychiatric problems during the course of the disease. In 52 (37%), the nervous system manifestations were secondary to SLE. 2. The most frequent manifestations were psychiatric dysfunction, seizures, long tract signs, cranial neuropathy, and peripheral neuropathy. 3. Psychiatric abnormalities secondary to SLE were characterized by organic features (present in 22 of 24) and by the association of neurologic lesions which were often diffuse or multifocal. 4. An abnormal cerebrospinal fluid was found in 32% of neuropsychiatric episodes in which specimens were obtained. The most frequently abnormal study was the electroencephalogram (71%), and the least frequent was the brain scan (8%). These studies did not correlate with specific clinical patterns. 5. In 63% of the patients, NP manifestations preceded the diagnosis of SLE or occurred within the first year of diagnosed disease, and in most episodes were associated with evidence of clinical and/or serologic activity of the underlying illness. 6. Only two clinical features showed significant and striking correlations with neuropsychiatric involvement, namely vasculitis and thrombocytopenia. The possible pathogenic implications have been discussed. 7. Only 2 of the 140 patients were felt to have steroid-induced psychoses. In approximately one-half of the NP episodes secondary to SLE, patients were receiving no corticosteriods on presentation. Of those developing while patients were on steroids, the majority occurred on low doses or after tapering from higher levels. 8. The immediate prognosis for improvement in neuropsychiatric function was good with 84% of episodes showing complete or partial resolution. Corticosteroids appeared to be of benefit in a substantial number of patients although their precise role is difficult to quantitate. 9. Five and 10 years survivals for the overall population were 94% and 82%, respectively. There were no significant differences in survival for patients with or without nervous system involvement.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 781466     DOI: 10.1097/00005792-197607000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  85 in total

Review 1.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 2.  [Differential diagnosis of chronic inflammatory diseases of the central nervous system. Cerebrospinal fluid diagnosis and immunological parameters].

Authors:  D Reske; H-F Petereit
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

Review 3.  Attributing psychopathology to systemic lupus erythematosus: some methodological considerations.

Authors:  G L Iverson; L M McCracken
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

4.  Hippocampal atrophy in systemic lupus erythematosus.

Authors:  S Appenzeller; A D Carnevalle; L M Li; L T L Costallat; F Cendes
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

Review 5.  The central nervous system in systemic lupus erythematosus.

Authors:  M A Khamashta; R Cervera; G R Hughes
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

Review 6.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

7.  Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).

Authors:  R M Andrade; G S Alarcón; L A González; M Fernández; M Apte; L M Vilá; G McGwin; J D Reveille
Journal:  Ann Rheum Dis       Date:  2007-09-17       Impact factor: 19.103

8.  Systemic lupus erythematosus in Saudi patients.

Authors:  S R Alballa
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

9.  Systemic lupus erythematosus presenting as catatonic schizophrenia.

Authors:  M Tishler; A L Abramov
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

Review 10.  Acute transverse myelopathy complicating systemic lupus erythematosus.

Authors:  D J Propper; R C Bucknall
Journal:  Ann Rheum Dis       Date:  1989-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.